IQVIA Inc.
IQVIA Inc. is a leading global provider of advanced analytics, technology solutions, and clinical research services, operating with an extensive client base across more than 100 countries. As a prominent player in the Real World Evidence (RWE) market, IQVIA leverages its massive and varied data infrastructure, which includes electronic health records (EHRs), claims data, and other real-world datasets. The company is a key partner for evidence generation and safety studies, generating RWE insights at scale by combining clinical, claims, and patient-level information. This vast data access is crucial for providing deep insights into patient outcomes, treatment patterns, and healthcare utilization. Furthermore, IQVIA has developed a transformative RWE platform specifically for running clinical trials. Its technology integrates centralized data management, powerful analytics, and robust compliance measures—including data encryption and access controls—to ensure greater efficiency, collaboration, and security in the trial process. By applying AI and predictive modeling, IQVIA also assists in analyzing treatment outcomes, particularly in support of regulatory and payer RWE use cases, cementing its position as a strategic backbone for next-generation RWE solutions globally.
Latest Market Research Report on Real World Evidence Solutions Download PDF Brochure Now
Aetion Inc.
Aetion Inc. is a dedicated healthcare technology company specializing in scientifically rigorous Real World Evidence (RWE) solutions. The company’s core offering is the Aetion Evidence Platform™, a sophisticated tool designed to transform diverse Real-World Data (RWD)—such as electronic health records, claims, and registries—into transparent, reproducible, and actionable information on the value, safety, and efficacy of medical treatments. Aetion has distinguished itself by focusing on strong methodology and providing audit-ready analytics, making its platform a trusted resource for life sciences firms, payers, health technology assessment organizations, and global regulators like the FDA and EMA. The company’s framework is critical for generating evidence that supports key healthcare decisions and regulatory submissions. Aetion’s suite of tools, including Discover, Substantiate, and Generate, empowers researchers and clinicians to conduct scientifically sound studies with data transparency at the core, facilitating the growing regulatory acceptance of RWE. Its commitment to reproducibility and methodological rigor positions Aetion as a crucial enabler in the industry’s shift toward evidence-based healthcare.
Flatiron Health
Flatiron Health is a leading health technology company based in New York City, which has carved out a specialty in transforming oncology care through Real World Evidence (RWE). The company’s focus is on drawing RWE from high-quality, structured data extracted from electronic health records (EHRs) across a vast network of cancer centers. This specialization provides researchers with unparalleled access to reliable, structured oncology datasets that capture critical patient journeys, treatment patterns, and outcomes in the real world. Flatiron’s RWE is instrumental in supporting oncology research and evidence generation, significantly advancing the understanding of how cancer treatments perform outside of traditional clinical trial settings. The company has active collaborations with cancer centers and regulators, demonstrating its commitment to generating regulatory-grade evidence that can impact treatment development and clinical practice. By converting the complex and often fragmented data from routine cancer care into standardized RWE, Flatiron Health is instrumental in accelerating research, supporting comparative effectiveness studies, and ultimately improving patient outcomes in the fight against cancer.
ICON plc
ICON plc, headquartered in Dublin, Ireland, is a global contract research organization (CRO) and provider of integrated clinical and real-world research solutions. The company’s Real World Solutions division plays a vital role in connecting data generated during clinical trials with post-market real-world outcomes, supporting a product’s entire lifecycle from development through commercialization. ICON leverages its global operational reach and deep expertise to conduct a wide range of real-world studies, including epidemiological research, safety surveillance, and market access research across various therapeutic areas. Their comprehensive approach supports the demonstration of product value to payers and regulators by providing robust evidence of treatment effectiveness and safety in diverse patient populations. By integrating its clinical trial capabilities with patient outcomes research, ICON helps clients move beyond siloed data views to create a more complete and evidence-based narrative for their assets. This integrated strategy makes ICON a strategic partner for pharmaceutical and medical device companies navigating the increasingly complex environment of real-world evidence generation.
Optum Life Sciences
Optum Life Sciences is a division of Optum, Inc., a major US-based healthcare organization and a subsidiary of UnitedHealth Group, giving it a unique advantage in the Real World Evidence (RWE) market through deep access to integrated healthcare data. Optum Life Sciences leverages extensive claims data, electronic health records (EHRs), and provider network data across the United States. Through its Optum Insight segment, the company helps life sciences companies, payers, and providers understand real-world treatment patterns, optimize the efficiency of the healthcare system, and demonstrate the value of new therapies. Their RWE solutions are characterized by the integration of healthcare, claims, and genomic data, coupled with advanced predictive and comparative analytics. This allows for sophisticated analyses that support health economics, adherence to compliance requirements, and enhanced clinical performance. Optum’s payer and health economics expertise, combined with its vast, integrated data platform, positions it as a market leader in delivering actionable, payer-driven insights for real-world value demonstration and improved patient well-being.
Merative
Merative, formerly known as IBM Watson Health, emerged as an independent entity in 2022 under Francisco Partners, focusing on the mission to help healthcare organizations reconstruct information and gain deep insights to enhance healthcare delivery, decision-making, and overall performance. The company holds a leading position in the Real World Evidence (RWE) solutions market, providing crucial data assets that enable comprehensive patient journey analysis. Merative’s flagship RWE offerings include the Merative MarketScan Research Databases and the Merative Explorys EHR Database. These extensive, de-identified datasets, which link healthcare claims data, are vital resources for research and commercial evidence strategies. They allow users to conduct in-depth, longitudinal analyses across patient populations, treatment patterns, and healthcare utilization. By providing these essential data infrastructures, Merative supports life science firms and healthcare stakeholders in generating robust RWE to improve clinical outcomes and operational efficiency, solidifying its role as a key purveyor of foundational RWE data assets.
SAS Institute Inc.
SAS Institute Inc. is a well-established global supplier of advanced analytics, artificial intelligence (AI), and data management software and services, providing the foundational technological tools essential for scalable Real World Evidence (RWE) generation. While not a dedicated RWE data provider, SAS’s platforms, including SAS, SAS Viya, and JMP, are indispensable for pharmaceutical and healthcare organizations. These solutions enable the sophisticated management and analysis of the massive and complex real-world datasets (RWD) necessary to derive meaningful RWE. In the RWE domain, SAS empowers users to build predictive models, perform statistical analyses, and generate high-confidence insights on treatment efficacy and safety. The company’s technology facilitates the integration of various data sources, transforming raw RWD into structured, evidence-grade information for decision-making across life sciences, finance, and the public sector. By offering best-in-class analytical infrastructure, SAS is a critical enabling partner for companies generating and leveraging RWE at an enterprise scale.
Komodo Health
Komodo Health is a healthcare technology business recognized for its proprietary “Healthcare Map,” a comprehensive, de-identified, longitudinal data platform that meticulously tracks patient journeys across the United States. This extensive data asset is a cornerstone for the company’s Real World Evidence (RWE) solutions. Komodo Health’s platform integrates data from various sources, giving stakeholders an unprecedented view of patient movements, disease progression, and treatment patterns over time. The company’s user-friendly tools, such as MapLab and MapView, enable sophisticated visualization and analysis, allowing life sciences firms and other healthcare stakeholders to effectively generate RWE. This capability is vital for use cases such as identifying unmet patient needs, understanding disease trends, optimizing clinical trial design, and supporting commercial strategies. By transforming complex, real-world data into insightful RWE, Komodo Health empowers pharmaceutical companies and researchers to accelerate drug discovery, improve clinical outcomes, and ultimately reduce the burden of disease globally.
Veradigm
Veradigm is a healthcare technology company focused on leveraging its robust network to provide comprehensive Real-World Evidence (RWE) solutions and services. With roots tracing back to Allscripts, Veradigm now brandishes solutions across electronic health records (EHRs), practice management systems, and a powerful RWE Analytics Platform. Veradigm offers end-to-end RWE generation support, including data and platform-enabled research services that cover the entire spectrum of evidence generation. Their capabilities range from facilitating retrospective studies to managing prospective, low-intervention observational studies, and even collaborating with Contract Research Organizations (CROs) to support clinical trials. A key strength is its direct access to a broad and diverse patient population through its network, ensuring the data is high-quality and current. The company also specializes in data management, risk adjustment, and quality management, helping researchers focus on RWD analysis rather than data curation. Veradigm’s integration of data, analytics, and clinical workflow tools makes it a critical enabler of evidence-based medicine.
Certara
Certara is a global leader in biosimulation, consulting, and technology services, with a dedicated focus on Real-World Evidence (RWE) solutions that span the entire product lifecycle. The company’s RWE Services leverage over a century of collective expertise in the design and execution of real-world data studies, providing robust solutions to bridge the gap between controlled clinical trials and actual patient outcomes. Certara employs best-in-class modeling and advanced analytics to deliver unparalleled insights, ensuring that its clients’ strategies are both scientifically sound and data-driven. Key capabilities include Health Economics and Outcomes Research (HEOR), patient and drug registry design, post-approval safety studies, and market access strategy. By helping pharmaceutical companies articulate the real-world value of their treatments, Certara is instrumental in supporting market access and value demonstration efforts. This comprehensive, patient-centered approach, backed by deep scientific expertise, positions Certara as a trusted partner for harnessing RWE to make informed drug development and commercialization decisions.
Latest Market Research Report on Real World Evidence Solutions Download PDF Brochure Now